Natco Pharma informs about outcome of board meeting

25 Sep 2025 Evaluate
Natco Pharma has informed that the Board of Directors at their meeting held today, September 25, 2025, has given their in-principle approval to evaluate the demerger of the Agro business of the Company into a separate entity. The management believes that this move shall enable value unlocking of the core business (pharmaceuticals) and enhance long-term growth. Further, it also provides operational flexibility, focused and dedicated management (for respective businesses), different brand positioning for each legal entity. As a part of the proposed reorganization, the Company may retain a small minority stake in the resulting company. This is to support the company in terms of common services such as R&D, Patents, etc. Support via Transitional Service Agreements (TSAs) at arm’s length pricing. Board has authorized the management to undertake detailed evaluation of the proposed demerger suggesting optimal capital & shareholding structure as indicated above and present to the Audit Committee and Board of Directors.

The above information is a part of company’s filings submitted to BSE.

Natco Pharma Share Price

933.60 -15.25 (-1.61%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×